# A Phase I/II Study of Intratumoral Injection of SD-101

> **NCT02254772** · PHASE1,PHASE2 · COMPLETED · sponsor: **Robert Lowsky** · enrollment: 9 (actual)

## Conditions studied

- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **DRUG:** SD-101
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT02254772
- **Lead sponsor:** Robert Lowsky
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-11-10
- **Final completion:** 2017-01-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254772, "A Phase I/II Study of Intratumoral Injection of SD-101". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02254772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*